Invitrogen Corporation (Nasdaq:IVGN) today announced results for its second quarter ended June 30, 2006. Revenues for the second quarter were $314 million, an increase of 2% over the $306 million reported for the second quarter of 2005. Foreign currency translation had minimal effect on sales growth rate. Net income for the second quarter was $20 million versus $15 million for the same quarter in 2005. GAAP earnings per share for the second quarter of 2006 were $0.36 per share, as compared to $0.27 per share reported in the second quarter of 2005, an increase of 33%. Earnings per share in 2006 includes lower expenses associated with the write up of acquisition inventory to fair market value as a result of a business combination and a gain on the sale of the company’s German contract manufacturing business in April.
